SGMC Health now offers in-house HER2 testing for breast cancer, making it the only provider within a 150-mile radius to offer ...

The refusal of blood transfusions by Jehovah’s Witnesses poses a major challenge in treating acute myeloid leukaemia (AML), ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...

This study presents a useful inventory of genes that are up- and down-regulated in the mouse small intestine (duodenum and ileum) during the first postnatal month; the data were collected and analyzed ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Researchers created a new wheat line by adding genetic material from a related grass, improving its ability to withstand ...